Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

기사 요약

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.